Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.485
+0.045 (3.13%)
Nov 3, 2026, 11:03 AM EST - Market open
Lexicon Pharmaceuticals Market Cap
Lexicon Pharmaceuticals has a market cap or net worth of $660.76 million as of November 3, 2026. It is the 12,712th most valuable company in the world and the 2,548th biggest in the United States. Its market cap has increased by 31.76% in one year.
Market Cap
660.76M
Enterprise Value
529.39M
1-Year Change
31.76%
Global Rank
Country Rank
#2,548 United States
Category
ChartMarket Cap Chart
Since April 7, 2000, Lexicon Pharmaceuticals's market cap has decreased from $890.90M to $660.76M, a decrease of -25.83%. That is a compound annual growth rate of -1.12%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 3, 2026 | 660.76M | 58.11% |
| Dec 31, 2025 | 417.90M | 56.46% |
| Dec 31, 2024 | 267.10M | -28.72% |
| Dec 29, 2023 | 374.70M | 3.94% |
| Dec 30, 2022 | 360.50M | -38.54% |
| Dec 31, 2021 | 586.60M | 45.99% |
| Dec 31, 2020 | 401.80M | -8.89% |
| Dec 31, 2019 | 441.00M | -37.30% |
| Dec 31, 2018 | 703.30M | -32.58% |
| Dec 29, 2017 | 1.04B | -27.50% |
| Dec 30, 2016 | 1.44B | 4.32% |
| Dec 31, 2015 | 1.38B | 194.45% |
| Dec 31, 2014 | 468.40M | -49.30% |
| Dec 31, 2013 | 923.80M | -18.41% |
| Dec 31, 2012 | 1.13B | 159.94% |
| Dec 30, 2011 | 435.60M | -10.39% |
| Dec 31, 2010 | 486.10M | 62.74% |
| Dec 31, 2009 | 298.70M | 55.98% |
| Dec 31, 2008 | 191.50M | -53.80% |
| Dec 31, 2007 | 414.50M | 50.51% |
| Dec 29, 2006 | 275.40M | 16.89% |
| Dec 30, 2005 | 235.60M | -52.10% |
| Dec 31, 2004 | 491.90M | 33.02% |
| Dec 31, 2003 | 369.80M | 49.35% |
| Dec 31, 2002 | 247.60M | -58.67% |
View and export this data all the way back to 2000. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| 4D Molecular Therapeutics | 657.41M |
| Candel Therapeutics | 637.40M |
| Aura Biosciences | 636.75M |
| Immix Biopharma | 636.69M |
| Iambic Therapeutics | 636.59M |
| Aclaris Therapeutics | 615.29M |
| Adlai Nortye Group | 615.00M |
| Olema Pharmaceuticals | 612.48M |